Pilot Study to Enhance HIV Care Using Needle Exchange-Based Health Services for Out-of-Treatment Injecting Drug Users

Journal of Urban Health

Volumn 80, Issue 3, 2003, Pages 416-427

  Altice, Frederick L ^a   Springer, Sandra ^a   Buitrago, Marta ^a   Hunt, David P ^a   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral therapy; Directly observed therapy; Health care; HIV therapeutics; HIV AIDS; Injecting drug users; Intervention; Needle exchange; Substance abuse; Substance abuse treatment

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIAMORPHINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PLACEBO; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; METHADONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; DIRECTLY OBSERVED THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MALE; MORTALITY; NEEDLE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; TECHNIQUE; UNITED STATES; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; ETHNIC GROUP; HEROIN DEPENDENCE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; SUBSTANCE ABUSE; UTILIZATION REVIEW; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONNECTICUT; DIRECTLY OBSERVED THERAPY; ETHNIC GROUPS; FEMALE; HEROIN DEPENDENCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHADONE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; PATIENT COMPLIANCE; PILOT PROJECTS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 0142151386     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jtg053     Document Type: Article

References (58)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Update: trends in AIDS incidence-United States. MMWR Morb Mortal Wkly Rep. 1996;46:861-867.
3. Whitman S, Murphy J, Cohen M, et al. Marked declines in HIV related mortality in Chicago in women, African Americans, Hispanics, young adults, and IDU's, from 1995 through 1997. Arch Intern Med. 2000;160:365-369.
4. Bamberger JD, Unick J, Klein P, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90:699-701.
5. Ferrando SJ, Wall TL, Batki SL, et al. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475-487.
6. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-502.
7. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665-1670.
8. Wall TL, Sorensen JL, Batki SL, et al. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995;37:261-269.
9. Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439-447.
10. Williams A, Friedland GH. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51-54, 58.
11. Williams AB, Friedland GH. Substance abuse issues in women with HIV. In: Cotton DJ, Watts DH, eds. Medical Management of AIDS in Women. New York, NY: John Wiley and Sons; 1996;437-453.
12. Celantano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
13. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
14. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med. 1994;331:450-459.
15. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med. 1989;111:761-763.
16. O'Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med. 1992;93:382-386.
17. Selwyn PA, Budner NS, Wasserman WC, et al. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108:492-500.
18. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.
19. Dixon PS, Flanigan TP, DeBuono BA, et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med. 1993;95:629-635.
20. Mostashari F, Riley E, Selwyn PA, et al. Acceptance and adherence of antiretroviral therapy among HIV infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341-348.
21. Heimer R, Kaplan EH, O'Keefe E, et al. Three years of needle exchange in New Haven: what have we learned? AIDS Public Policy J. 1994;9:59-74.
22. Barry M, Fleck E, Lentz S, Bell C, O'Connor P, Horwitz R. "Medicine on wheels": an opportunity for outreach and housestaff education. Conn Med. 1994;58:535-539.
23. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
24. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:83-88.
25. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:461-466.
26. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
27. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
28. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999;13:2547-2554.
29. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
30. Cheever LW, Wu AW. Medication adherence among HIV-infected patients: understanding the complex behavior of patients taking this complex therapy. Curr Infect Dis Rep. 1999;1:401-407.
31. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195-205.
32. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115-1123.
33. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA. 1998;280:567-568.
34. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis. 1999;28:643-676.
35. Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797-804.
36. The AVANTI Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet. 1999;353:2061-2064.
37. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511-518.
38. Mitty JA, Stone VE, Sands M, et al. Directly Observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34:984-990.
39. Babudieri S, Aceti A, D'Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179-180.
40. Fischl M, Rodriguez, A, Scerpella R, et al. Impact of directly observed therapy on outcomes in HIV clinical trials. In: Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 71.
41. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
42. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-868.
43. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000;14:1545-1552.
44. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Resp J. 1998;12:967-971.
45. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468-480.
46. Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Reader. 2002;12:305-307, 312-316.
47. Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA. 1999;282:1334.
48. Paterson DL, Swindells S, Mohr J, et. al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
49. Arnsten JH, Demas PA, Farzadegan H, et. al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
50. Daar ES, Cohen C, Remien R, et al. Improving adherence to antiretroviral therapy. AIDS Reader. 2003;13:81-90.
51. McPherson-Baker S, Malow RM, Penedo F, et al. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12:399-404.
52. Malow RM, McPherson S, Klimas N, et al. Alcohol and drug abuse: adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998;49:1021-1024.
53. Pollard RB. Can HIV infection be treated successfully with a once-daily regimen? AIDS Reader. 2002;12:489-500.
54. Liebman J, Pat Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs. 2002;19(5):345-353.
55. Pollack HA, Khoshnood K, Blankenship KM, et al. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002;17:341-348.
56. Leidy NK. Operationalizing Maslow's theory: development and testing of the basic need satisfaction inventory. Issues Ment Health Nurs. 1994;15:277-295.
57. Craig RJ, Olson RE. Differences in psychological need hierarchy between program completers and dropouts from a drug abuse treatment program. Am J Drug Alcohol Abuse. 1988;14:89-96.
58. Acton GJ, Malathum P. Basic need status and health-promoting self-care behavior in adults. West J Nurs Res. 2000;22:796-811.